Format

Send to

Choose Destination
Surg Clin North Am. 2014 Oct;94(5):1003-15, viii. doi: 10.1016/j.suc.2014.07.004. Epub 2014 Aug 7.

Locoregional therapies in melanoma.

Author information

1
Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, SRB 4.24012, Tampa, FL 33612, USA.
2
Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, SRB 4.24012, Tampa, FL 33612, USA. Electronic address: jonathan.zager@moffitt.org.

Abstract

In-transit disease is defined as any dermal or subcutaneous metastases that arise between the primary melanoma but not beyond the draining regional nodal basin. Patients who develop in-transit disease are at further risk to develop additional locoregional and distant disease. Treatment must be individualized and take into consideration the extent of disease, tumor characteristics, and patient characteristics including age, comorbidities, previous therapies, and site of recurrence. Surgery, regional perfusions and intralesional injections all play a role in management options. These patients should be discussed and managed by a multidisciplinary team whenever possible.

KEYWORDS:

Hyperthermic isolated limb perfusion; Intra-tumoral injections; Isolated limb infusion; Locoregional recurrence; Melanoma

PMID:
25245964
DOI:
10.1016/j.suc.2014.07.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center